Jefferies Financial Group Inc. Takes $5.93 Million Position in Biogen Inc. $BIIB

Jefferies Financial Group Inc. bought a new stake in Biogen Inc. (NASDAQ:BIIB) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 27,463 shares of the biotechnology company’s stock, valued at approximately $5,934,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Bell Investment Advisors Inc bought a new stake in Biogen during the second quarter worth approximately $27,000. Reflection Asset Management acquired a new position in shares of Biogen during the 4th quarter valued at $25,000. Root Financial Partners LLC raised its stake in shares of Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after buying an additional 123 shares in the last quarter. MV Capital Management Inc. acquired a new stake in shares of Biogen in the fourth quarter valued at $34,000. Finally, Strive Financial Group LLC bought a new position in Biogen during the fourth quarter valued at about $35,000. 87.93% of the stock is currently owned by institutional investors.

Biogen Trading Down 1.4%

Shares of NASDAQ:BIIB opened at $218.50 on Friday. The firm has a fifty day moving average of $207.81 and a two-hundred day moving average of $195.68. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen Inc. has a 12-month low of $131.52 and a 12-month high of $222.85. The firm has a market capitalization of $32.28 billion, a P/E ratio of 38.67, a price-to-earnings-growth ratio of 6.90 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. The business had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. Biogen’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the prior year, the business posted $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, equities analysts expect that Biogen Inc. will post 12.39 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on BIIB shares. Barclays boosted their price target on shares of Biogen from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 29th. Guggenheim raised their target price on shares of Biogen from $260.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Jefferies Financial Group restated a “buy” rating on shares of Biogen in a research report on Monday, July 13th. Wedbush increased their price objective on Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, July 30th. Finally, UBS Group lifted their target price on Biogen from $225.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $227.79.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.